KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Cash from Investing Activities (2019 - 2025)

Historic Cash from Investing Activities for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to -$958.3 million.

  • Royalty Pharma's Cash from Investing Activities rose 1965.18% to -$958.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 billion, marking a year-over-year increase of 5990.9%. This contributed to the annual value of -$2.7 billion for FY2024, which is 2920.35% down from last year.
  • As of Q3 2025, Royalty Pharma's Cash from Investing Activities stood at -$958.3 million, which was up 1965.18% from -$312.0 million recorded in Q2 2025.
  • In the past 5 years, Royalty Pharma's Cash from Investing Activities registered a high of $503.9 million during Q1 2025, and its lowest value of -$1.4 billion during Q3 2022.
  • For the 5-year period, Royalty Pharma's Cash from Investing Activities averaged around -$443.0 million, with its median value being -$505.6 million (2024).
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first tumbled by 510247.2% in 2023, then surged by 68155.45% in 2025.
  • Over the past 5 years, Royalty Pharma's Cash from Investing Activities (Quarter) stood at -$551.6 million in 2021, then soared by 175.18% to $414.7 million in 2022, then plummeted by 341.16% to -$1.0 billion in 2023, then skyrocketed by 49.45% to -$505.6 million in 2024, then crashed by 89.54% to -$958.3 million in 2025.
  • Its Cash from Investing Activities stands at -$958.3 million for Q3 2025, versus -$312.0 million for Q2 2025 and $503.9 million for Q1 2025.